Introduction
============

The role of the D allele of the angiotensin-converting enzyme (ACE) gene I/D polymorphism in the clinical outcomes of patients with acute lung injury and acute respiratory distress syndrome (ALI/ARDS) remains controversial. We assessed simultaneously the effect of the ACE I/D polymorphisms as well as the serum and BALF ACE levels on prognosis of ARDS patients.

Methods
=======

We recruited 69 mechanically ventilated ALI/ARDS patients. ACE activity levels in serum and BALF were assessed by chemical methods. Patients were genotyped for ACE I/D polymorphisms. Time-to-event analysis evaluated the variables associated with the 28-day and 90-day mortality.

Results
=======

In the multivariable model, age, lung compliance, serum lactate and serum ACE levels were significantly associated with both 28-day and 90-day mortality. No significant correlation was found between serum and BALF ACE levels (Spearman\'s ρ = 0.054; *P*= 0.66). Serum ACE concentrations were significantly higher (*P*= 0.046) in patients with D/D genotype versus the two other groups combined (I/D and I/I genotypes). A meta-analysis of six studies (including ours) provided evidence that the D allele is significantly associated with increased mortality in ALI/ARDS patients, yielding a per-allele odds ratio of 1.76 (95% CI: 1.19 to 2.59). See Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}.
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###### 

Characteristics of the study population (*n*= 69)

  --------------------------------- ---------------------------------
  Age (years)                       64.4 ± 17.9; 69 (28 to 89)
  Sex (males, %)                    43 (62.3%)
  APACHE II score                   22.1 ± 6.2; 21 (14 to 35)
  SOFA score                        8.4 ± 3.2; 8 (4 to 16)
  Lung compliance (ml/cmH~2~O)      29.4 ± 7.2; 30 (17 to 40)
  PaO~2~/FiO~2~                     139, 1 ± 47.1; 140 (72 to 223)
  PEEP                              8.1 ± 2.9; 8 (5 to 15)
  Lung Injury Score                 2.5 ± 0.6; 2.5 (1.75 to 3.50)
  Blood lactate (mmol/l)            1.7 ± 1.7; 1.3 (0.5 to 5.2)
  Septic status                     39 (56.5%)
  Serum ACE (U/l)                   16.5 ± 10.8; 13.6 (4.8 to 39.8)
  BALF (U/l)                        2.3 ± 1.4; 2.0 (0.3 to 4.7)
  ACE I/D polymorphism:             
   *D/D*                            27 (39.1%)
   *I/D*                            28 (40.6%)
   *I/I*                            14 (20.3%)
  28-day mortality                  34/69 (49.3%)
  90-day mortality                  43/69 (62.3%)
  Ventilator-free days              5.1 ± 7.8; (0 to 23)
  Days w/o cardiovascular failure   14.0 ± 10.2; 16 (0 to 27)
  Days w/o renal failure            15.4 ± 10.6; 16 (0 to 28)
  --------------------------------- ---------------------------------

Conclusion
==========

Serum ACE levels appear to be affected by the I/D polymorphism and are correlated with prognosis in patients with ALI/ARDS, indicating that further investigation of the clinical significance of the ACE in ARDS might be of value.
